Driver R. Tessier, D. Nicolau; Hartford Hosp., Hartford, CT. F-2022

198 SCIENTIFIC SESSIONS September 9-12 | F-2010 Antimicrobial Activity of EDTA Containing Nanoemulsions on MDR Acinetobacter baumannii

K. Ramalingam

1 , Y. Y. Hwang 2 , V. Lee 1 , A. Rene 2 ; 1 Univ. of Texas Hlth. Sci. Ctr., San Antonio, TX, 2 Naval Med. Res. Unit, San Antonio, TX. F-2011 Antibacterial Activity of Daptomycin and Vancomycin-Load- ed Polymeric Particulate Systems for Bone Infections Treatment

I. S. Ferreira

1 , B. Betrisey 2 , A. Bettencourt 1 , A. J. Almeida 1 , A. Trampuz 2 ; 1 Univ. of Lisbon, Lisbon, Portugal, 2 Univ. Hosp., Lausanne, Switzerland. F-2012 Glyceryl Trinitrate GTN is Useful as a Novel Non-Antibi- otic Catheter Lock for the Prevention of Intraluminal Catheter Biofilm Colonisation J. Rosenblatt, R. Y. Hachem, T. Dvorak, A. Chaftari, M. Alshuabi, I. I. Raad; U.T.M.D. Anderson Cancer Ctr., Houston, TX. F-2013 Augmenting Antibiotic-Coated Catheters CVC Activity against Bacterial Biofilm Adherence by Impregnating the Cvc with Verapamil J. A. Mohamed, A. Chaftari, R. Y. Hachem, M. Alshuaibi, I. I. Raad; U.T.M.D. Anderson Cancer Ctr., Houston, TX. F-2014 Pathogenesis and Prevention of Ventilator-Associated Pneu- monia VAP: An in Vitro Model Using Antimicrobial-Coated Endotracheal Tube ETT J. Rosenblatt, R. Y. Hachem, R. Reitzel, A. Chaftari, I. I. Raad; U.T.M.D. Anderson Cancer Ctr., Houston, TX. F-2015 Barrier-Forming Oral Formulation Containing Cetylpyri- dinium Chloride fCPC Exhibits Potent Activity against Oral Pathogens J. Chandra 1 , P. K. Mukherjee 1 , F. Esper 2 , A. M. Ghannoum 3 , B. Sokol 3 , R. A. Salata 2 , M. A. Ghannoum 4 ; 1 Case Western Reserve Univ., Cleveland, OH, 2 Univ. Hosp. Case Med. Ctr., Cleveland, OH, 3 Oasis Consumer Health- care LLC, Cleveland, OH, 4 Univ. Hosp. Case Med. Ctr. and Case Western Reserve Univ., Cleveland, OH. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. ------------------------------------------------------------------------ 247 F Poster Session Novel Inhibitors of Bacterial GyrBParE Topoisomer- ase Subunits Wednesday, 9:15 a.m.–11:15 a.m. . . . . . . . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: F-2016 In Vitro and In Vivo Biology of Benzothiazole Urea-Based, Dual-Targeting DNA Supercoiling Inhibitors for the Treatment of Bacterial Infections

J. T. Palmer

1 , S. Barker 2 , J. M. Bennett 2 , J. Berry 2 , M. Blair 1 , L. G. Czaplewski 2 , I. Collins 2 , D. Davies 2 , D. J. Haydon 2 , P. Lancett 2 , A. Logan 2 , C. J. Lunniss 1 , C. Morton 1 , G. R. W. Pitt 1 , D. Offermann 1 , L. Offermann 1 , S. Pommier 2 , D. Price 2 , N. Stokes 2 , H. Thomaides-Brears 2 , S. P. Tucker 1 ; 1 Biota Scientific Management, Notting Hill, Australia, 2 Biota Europe, Beg- broke, United Kingdom. F-2017 Antibacterial Agents Targeting DNA Gyrase B and Topoisomerase IV: Discovery of a New Class by Structure-Based Drug Design

X. Li

1 , L. W. Tari 1 , D. Bensen 1 , M. Trzoss 1 , T. Lam 1 , J. Zhang 1 , Z. Chen 1 , S. J. Lee 1 , M. Cunningham 1 , K. Nelson 1 , V. Brown-Driver 1 , M. Stidham 1 , T. Nguyen 2 , F. Lightstone 2 , K. Shaw 1 , J. Finn 1 ; 1 Trius Therapeutics, Inc., San Diego, CA, 2 Lawrence Livermore Natl. Lab., Livermore, CA. F-2018 Antibacterial Agents Targeting DNA Gyrase B and Topoi- somerase IV: Optimization of Gram-Negative Antibacterial Activity and Drug Properties

J. Finn

1 , M. Trzoss 1 , X. Li 1 , D. Bensen 1 , T. Lam 1 , J. Zhang 1 , Z. Chen 1 , S. Lee 1 , M. Cunningham 1 , K. Nelson 1 , A. Castellano 1 , B. Kwan 1 , M. Stidham 1 , V. Brown-Driver, T. Nguyen 2 , F. Lightstone 2 , S. Wong 2 , K. J. Shaw 1 , L. W. Tari 1 ; 1 Trius Therapeutics, Inc., San Diego, CA, 2 Lawrence Livermore Natl. Lab., Livermore, CA. F-2018a Antibacterial Agents Targeting DNA Gyrase B and Topoi- somerase IV: Design of Compounds with Broad-Spectrum Gram- Negative Antibacterial Activity

L. Tar

1 , D. Bensen 1 , M. Trzoss 1 , X. Li 1 , T. Lam 1 , J. Zhang 1 , Z. Chen 1 , S. Lee 1 , M. Cunningham 1 , K. Nelson 1 , M. Stidham 1 , V. Brown-Driver 1 , T. Nguyen 2 , F. Lightstone 2 , S. Wong 2 , K. J. Shaw 1 , J. Finn 1 ; 1 Trius Therapeutics, San Diego, CA, 2 Lawrence Livermore Natl. Lab., Livermore, CA. F-2019 Potent Activity of Novel GyraseTopoisomerase Inhibitors against Gram-Negative and Gram-Positive Pathogens with Important Resistance Phenotypes

C. M. Pillar, L. Stapert, M. Marchak, D. L. Shinabarger; Micromyx, LLC, Kalamazoo, MI.

F-2020 Microbiological Profile of Novel Inhibitors of DNA Gyrase and Topoisomerase IV against Gram-Negative Pathogens K. Nelson, A. Castellano, S. Farkas, V. Brown-Driver, K. J. Shaw; Trius Therapeutics, San Diego, CA. F-2021 In Vitro Activity of Novel Gyrase Inhibitor Antimicrobials against Clinical Pseudomonas aeruginosa Isolates P. R. Tessier, D. P. Nicolau; Hartford Hosp., Hartford, CT. F-2022 Antimicrobial Activity and In Vivo Efficacy of Novel GyrB ParE Inhibitors versus Burkholderia pseudomallei

V. Driver

1 , N. Podnecky 2 , N. Marlenee 2 , R. Bowen 2 , X. Li 1 , K. J. Shaw 1 , H. P. Schweizer 2 ; 1 Trius Therapeutics, Inc., San Diego, CA, 2 Colorado State Univ., Fort Collins, CO. F-2023 Broad Spectrum Activity of Novel, Dual Targeting Inhibitors of Bacterial DNA Gyrase and Topoisomerase IV against Biode- fense Pathogens K. Montgomery 1 , G. Vanier 1 , K. Nelson 2 , V. Brown-Driver 2 , K. J. Shaw 2 , P. J. Jackson 1 ; 1 Lawrence Livermore Natl. Lab., Livermore, CA, 2 Trius Therapeutics, Inc., San Diego, CA. F-2024 Advanced Microbiological Profile of New DNA Gyrase Topoisomerase IV Inhibitors V. Brown-Driver, A. Castellano, K. Nelson, X. Li, T. Lam, M. Trzoss, J. Zhang, Z. Chen S. Lee, K. J. Shaw, J. Finn; Trius Therapeutics, San Diego, CA. F-2025 Selection and Characterization of E. coli Mutants with Reduced Susceptibility to Novel DNA GyraseTopoisomerase IV Inhibitors A. Castellano, J. Locke, S. Farkus, V. Brown-Driver, K. J. Shaw; Trius Therapeutics, Inc., San Diego, CA. 199 WEDNESDAY SCIENTIFIC SESSIONS Final Program F-2026 Comparative Pharmacokinetics of Novel Inhibitors of DNA GyraseTopoisomerase IV V. Ong, V. Brown-Driver, C. L. Hall, G. W. Hough, K. Nelson; Trius Therapeutics, Inc., San Diego, CA. F-2027 Use of Microdosing and Accelerator Mass Spectrometry to Evaluate the Pharmacokinetics of a Novel GyrBParE Inhibitor

M. A. Malfatti